PharmAla Biotech Holdings Inc. has contracted with a third-party logistics company specializing in pharmaceutical products to function as its US clinical trial distribution partner.
“PharmAla has noted over the past months that US-Canada cross-border shipping uncertainty has increased. This uncertainty is negatively impacting our numerous clinical trial customers in the United States,” said Nicholas Kadysh, CEO, PharmAla Biotech. “As our volume of business in the US grows, we are always looking for ways to optimize our work; with the potential imposition of tariff barriers, we believe that this is even more important. We are pleased to have contracted with an exceptionally capable partner to store and distribute our LaNeo™ clinical trial materials on behalf of both ourselves and our US clients.”
PharmAla’s agreement with its partner should provide for a streamlined warehoused, GMP-compliant supply of LaNeo™ MDMA for all current clients already contracted and should provide exceptional certainty against import/export risks for future clients seeking to purchase LaNeo™ MDMA for clinical trials in the United States.
The agreement is non-exclusive and does not include any provision for sales of LaNeo™ MDMA. The partner will act on PharmAla’s behalf only in the storage and directed distribution of PharmAla’s products. The name of PharmAla’s logistics partner is being withheld at their request. This follows the announcement, two weeks ago, that PharmAla had secured a permanent and exclusive licensed distribution agreement with Duchefa Farma in the Netherlands.